For an adult with typical bacterial conjunctivitis and no fluoroquinolone allergy, corneal ulceration, or recent ocular surgery, is ofloxacin 0.3% ophthalmic solution preferred over polymyxin B 0.1% ophthalmic solution as first‑line treatment?

Ofloxacin vs Polymyxin for Bacterial Conjunctivitis

For typical bacterial conjunctivitis in an adult without contraindications, neither ofloxacin nor polymyxin B is inherently superior—the most recent 2024 AAO guidelines explicitly state there is "no clinical evidence suggesting the superiority of any particular antibiotic" for mild bacterial conjunctivitis, making the choice based on convenience and cost rather than efficacy 1.

Guideline-Based Approach

The 2024 Conjunctivitis Preferred Practice Pattern from the American Academy of Ophthalmology provides clear direction 1:

• Mild bacterial conjunctivitis is self-limited and typically resolves spontaneously without treatment in immunocompetent adults
• Topical antibiotics provide earlier clinical and microbiological remission in days 2-5, with benefits persisting through days 6-10
• A 5-7 day course of any broad-spectrum topical antibiotic is usually effective
• Select the most convenient or least expensive option—there is no clinical evidence of superiority for any specific agent

Evidence Comparing These Agents

Ofloxacin Advantages:

• Superior ocular penetration: Achieves 2.4-fold higher aqueous humor concentrations than trimethoprim (1.135 vs 0.470 mcg/mL) 2
• Broader gram-negative coverage including Pseudomonas aeruginosa 3
• Less frequent dosing (typically QID vs polymyxin combinations)

Polymyxin B Considerations:

• Often combined with trimethoprim for broader coverage
• Requires QID dosing
• One pediatric study showed moxifloxacin (another fluoroquinolone) achieved faster symptom resolution than polymyxin/trimethoprim (81% vs 44% complete resolution at 48 hours) 4, though this doesn't directly compare ofloxacin

Critical Resistance Concerns

Important caveat: Fluoroquinolone resistance is emerging and should influence your decision:

• Coagulase-negative Staphylococcus shows 56.9% resistance to fluoroquinolones in recent surveillance 5
• S. epidermidis demonstrates 61.3% fluoroquinolone resistance 5
• Moraxella keratitis cases resistant to fluoroquinolones have been documented 6
• However, these bacteria remain sensitive to vancomycin and third-generation cephalosporins 5

Practical Recommendation Algorithm

For typical bacterial conjunctivitis without severe features:

1. Either agent is acceptable based on 2024 guidelines 1

2. Choose based on:

   • Cost and insurance coverage
   • Patient convenience (dosing frequency)
   • Local resistance patterns if known

3. Favor polymyxin B combinations if:

   • Cost is significantly lower
   • You want to preserve fluoroquinolone susceptibility in your community
   • Patient has had recent fluoroquinolone exposure

4. Favor ofloxacin if:

   • Gram-negative coverage is particularly important
   • Contact lens wearer (higher Pseudomonas risk)
   • Less frequent dosing improves compliance

5. Instruct patient to return in 3-4 days if no improvement 1—this is when you would escalate or culture

When This Decision Actually Matters

Moderate-to-severe bacterial conjunctivitis (copious purulent discharge, pain, marked inflammation) requires a different approach 1:

• Obtain cultures and Gram stain
• Consider MRSA coverage (many topical antibiotics ineffective)
• May require compounded vancomycin
• This scenario demands more aggressive therapy where agent selection becomes critical

Bottom line: The 2024 guidelines make clear that for uncomplicated bacterial conjunctivitis, your choice between these agents should prioritize practical factors over theoretical antimicrobial differences, as clinical outcomes are equivalent when used appropriately.